CVE-2025-22270

Stored XSS in CyberArk Endpoint Privilege Manager

Description

An attacker with access to the Administration panel, specifically the "Role Management" tab, can inject code by adding a new role in the "name" field. It should be noted, however, that the risk of exploiting vulnerability is reduced due to the required additional error that allows bypassing the Content-Security-Policy policy, which mitigates JS code execution while still allowing HTML injection. This issue affects CyberArk Endpoint Privilege Manager in SaaS version 24.7.1. The status of other versions is unknown. After multiple attempts to contact the vendor we did not receive any answer.

Category

7.3
CVSS
Severity: High
CVSS 4.0 •
EPSS 0.10%
Third-Party Advisory cert.pl Third-Party Advisory cert.pl
Affected: CyberArk Endpoint Privilege Manager
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2025-22270?
CVE-2025-22270 has been scored as a high severity vulnerability.
How to fix CVE-2025-22270?
To fix CVE-2025-22270, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2025-22270 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2025-22270 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2025-22270?
CVE-2025-22270 affects CyberArk Endpoint Privilege Manager.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.